Health Care

Labcorp's Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae Deal
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
What's Going On With Pfizer Stock On Thursday?
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
What's Going On With Pfizer Stock On Thursday?
Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions
AstraZeneca Posts Bumper Earnings On Strong Sales From Cancer Drugs, Sticks To Annual Guidance

Health Care Recent News

West Pharmaceutical Q1 Earnings Beat, HVP Sales Weak
West Pharmaceutical Services, Inc. (NYSE: WST) reported first-quarter 2024 adjusted earnings per share (ETF:EPS) of $1.56, which beat the Zacks Consensus Estimate by 20.9%. The bottom line, however, was down 21.2% year over year.
Drugmaker Sanofi's Strong Dupixent And Beyfortus Vaccine Sales Propel Q1 Earnings
Sanofi reports Q1 operating income at 2.8 billion euros, down 14.7%. Beat consensus EPS at $0.97. Sales reach $11.36 billion, led by Dupixent's 24.9% surge. Vaccine sales up 5.6%. Expecting Dupixent to hit €13 billion in 2024 sales. Blockbuster ambitions for Beyfortus.
What's Going On With Palantir Technologies Today?
Palantir Technologies (PLTR) shares dip premarket despite multi-year partnership with Parexel to enhance clinical trials efficiency using AI platforms.
US Warns Of E. Coli Risk With Eating Ground Beef: How To Keep Yourself Amid USDA Warning
The US FSIS has issued an E. coli health alert, but what E. coli is and how can you stay protected? Here's everything you need to know.
McKinsey Faces Criminal Probe By DOJ For Opioid Consulting: Report
The U.S. Department of Justice is conducting a criminal investigation into the consulting firm McKinsey & Company for its role in advising major opioid manufacturers on increasing sales. The investigation also focuses on potential obstruction of justice related to McKinsey's consulting records for opioid producers.
Viking Therapeutics Reports Q1 Results: 'An Exceptional Period' Says CEO
Viking Therapeutics reports quarterly losses of 26 cents per share which beat the analyst consensus estimate of losses of 28 cents by 7.14%. Research and development expenses were $24.1 million for the first quarter, compared to $11 million for the same period in 2023.
Advancements in Medical Device Innovation
ADM Tronics (OTC: ADMT) is a diversified technology company, specializing in the development and manufacturing of innovative products across three primary areas including Proprietary Electronic Medical Devices, Engineering, Regulatory, and Manufacturing Services, and Eco-Friendly, Water-Based Formulations.
Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why
Discover the challenges facing Leqembi, the first Alzheimer's drug shown to slow progression. Skepticism among doctors and concerns about efficacy and costs hinder widespread adoption despite FDA approval.
Humana Withdraws Its Already Lowered 2025 Profit Guidance
Humana revises 2025 profit forecast due to disappointing Medicare Advantage reimbursement rates. Medical benefit ratio up to 88.9% in Q1 2024. Adjusted EPS growth outlook impacted by pricing decisions for 2025 MA bids.
What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk
Senate Committee probes Novo Nordisk's pricing tactics for diabetes and obesity meds. Sanders demands transparency on pricing, signaling broader industry scrutiny. Medicare coverage expansion could impact millions, tackling accessibility challenges amidst rising costs.
Boston Scientific Lifts 2024 Profit Forecast On Strong Growth From Cardiovascular Devices, Stock Soars
Boston Scientific reports impressive Q1 earnings, with revenues of $3.86 billion, beating estimates. Cardiovascular segment leads with $2.4 billion sales, up 15.9%. Outlook: 2024 net sales growth forecasted at 11%-13%, adjusted EPS at $2.29-$2.34.
Biogen's Leqembi Commercial Ramp-Up Modest But Up Ticking, Reports Mixed Bag Q1 Earnings
Biogen reports Q1 results: adjusted EPS $3.67 (beat consensus), sales $2.29 billion (missed consensus). Leqembi launch uptake triples, Zurzuvae's early trends encouraging.
This Pioneering Cannabis Graduate Program Is A Blend Of Social Work And Marijuana, Here's Why Students Should Apply
Cannabis education is slowly paving its way toward entering medical schools with the research body growing exponentially over the past year. Simultaneously, there's a growing need for more knowledgeable medical cannabis experts nationwide as the stigma around the plant is fading and the therapeutic potential of cannabis in the U.S. is getting increasingly acknowledged. The University of Maryland School of Social Work (UMSSW) has teamed up with the School of Pharmacy to address the increased demand for more cannabis professionals. The collaboration resulted in a new dual graduate program - MSW and Medical Cannabis Science and Therapeutics Post Baccalaureate Certificate - for which UMB claims it's "only one in the country."

Explore Benzinga's Financial Tools

Find Stocks Tailored to Your Trading Interests
Find Stocks Tailored to Your Trading Interests
Benzinga Pro offers a real-time newsfeed as headlines break on earnings releases, analyst ratings, rumors, the biggest movers, and many more actionable alerts.

Compare Benzinga's Favorite Stock Brokers

Claim Exclusive Offers

Compare Benzinga's Favorite Cryptocurrency Brokers

Claim Exclusive Offers